Lybrate once put more than 150,000 doctors a text message away from any Indian patient, built on $14.43 million from Nexus Venture Partners, Tiger Global and Ratan Tata. Nine years after that first cheque, the company that helped pioneer India’s ask-a-doctor apps had its own co-founders suspended by the healthcare group that had just bought it, over money the founders said they were never fully paid.
The app is still live. The doctors are still listed. But the entity that ran the business reported revenue of just ₹11 lakh in FY25, a business that once claimed a turnover in the crores. This is the story of how a well-funded, well-networked telemedicine pioneer ended up as somebody else’s sales funnel.
Quick facts
| Company | Lybrate (Lybrate Inc / Lybrate Inc India Private Limited) |
| Founded | 2013, New Delhi/Gurugram (Inc42, TechCrunch; some trackers list 2014) |
| Founder(s) | Saurabh Arora (CEO) and Rahul Narang (CTO) |
| Businesses | Online doctor consultations, diagnostics (Lab+), doctor practice-management software (Cube); since 2022, largely a surgery-referral channel for Pristyn Care |
| Latest FY revenue | ₹11 lakh, FY25 (Inc42), down from ₹1.0 crore in FY24 — a fall of 89.1% year on year |
| Latest FY profit/loss | Not disclosed in public filings found this session |
| Listed | Private — not listed on any exchange |
| Market value / last valuation | Not officially disclosed. Total funding raised: $14.43 million lifetime. Inc42 (July 2023) estimated the 2022 acquisition deal at $20-30 million, unconfirmed by either party |
| Key shareholders / CEO | Acquired by Pristyn Care, June 2022. Co-founders Saurabh Arora and Rahul Narang were suspended by Pristyn Care in July 2023 (Entrackr, Inc42) |
What they do
Lybrate is an Indian online healthcare platform that lets patients search for doctors, ask health questions for free, and pay for text, audio or video consultations. Over the years it added a diagnostics arm (Lab+, for at-home sample collection) and a subscription tool for doctors to manage their own practices (Cube). As of September 2026, the platform lists over 150,000 doctors and describes itself on its own site as India’s “premier patient consulting portal,” with a presence across seven metro cities and dozens of tier-2 and tier-3 towns. Since being acquired by surgery-care company Pristyn Care in 2022, the site’s navigation now foregrounds a “Plan my Surgery” flow, and its footer credits Pristyn Care as its “Surgery Partner” — a shift from a broad consultation marketplace toward a narrower, single-buyer referral business.
The origin
Saurabh Arora studied mechanical engineering at IIT Delhi, then took an MBA at Columbia Business School, and spent roughly three and a half years at Facebook in the United States, where he worked connecting small and large advertisers to their customers through Facebook Ads. On a visit home, he watched pharmacy staff, untrained to prescribe, fielding questions from patients who had nowhere else to turn — a problem he judged far worse outside India’s big cities, where the doctor-to-patient ratio was thinner still. The insight he carried back from Facebook was simple: if an ad-matching engine could connect a business to a customer at scale, the same logic could connect a patient to a doctor. He co-founded Lybrate in 2013 with Rahul Narang, an engineer from YMCA University of Science and Technology in Faridabad who had been a lead software engineer at Snapdeal and, before that, a colleague of Arora’s at a media company. Narang took on the CTO role and built the product; Arora ran the business and the fundraising.
The struggle years
The first version of Lybrate, built in 2013, was a straightforward appointment-booking and practice-management tool. It did not work the way the founders hoped: doctors’ appointment slots were scarce and inflexible, and simply making booking easier did not fix the deeper problem of patients not being able to reach a doctor at all. By January 2015, Lybrate had pivoted to a communications platform built around three things instead — a public question-and-answer feed where patients posted problems anonymously and doctors answered, direct messaging between a patient and a chosen doctor, and a health-content feed written by doctors. That pivot, inside roughly eighteen months of founding, was the company’s first near-death moment: a business model built around booking slots simply had no way to scale.
The second problem surfaced once the new model found an audience. The founders themselves later pointed out that an average user might realistically consult a doctor only about a dozen times a year — nowhere near enough to build a subscription or high-frequency transaction business on consultations alone. That forced Lybrate to diversify: Lab+ launched in 2016 to add diagnostic test bookings, and Cube was built as a paid practice-management tool sold to doctors rather than patients, an attempt to find revenue on the supply side of the marketplace instead of relying purely on consultation fees. Meanwhile the competitive gap widened: by 2017, rival Practo had raised roughly $180 million against Lybrate’s cumulative $14.4 million or so, and had already expanded overseas, while Lybrate was still explaining to reporters that it planned to grow into India’s second and third-tier cities. Lybrate’s last disclosed institutional funding round closed in April 2017. No further external round was ever publicly reported for the next five years — a long capital drought for a consumer internet company in a capital-intensive sector, and one that ended not with a fresh round but with a sale.
The turning point
On 7 June 2022, Pristyn Care — a Tiger Global and Sequoia-backed surgical-care company — announced it had acquired Lybrate to expand into primary care and add an online-consultation front end to its own surgery-focused business. On one side of that transaction sat a company with a decade of brand recognition, a network of more than 150,000 doctors, tens of millions of recorded patient interactions, and $14.43 million of lifetime venture funding, but no fresh capital since 2017 and a business model that had never scaled into a self-sustaining, high-revenue company on its own. On the other side sat Pristyn Care, reported by Inc42 in 2023 to be valued at around $1.4 billion, looking for a ready-made pipeline of patients to feed into its elective-surgery funnel. The deal’s financial terms were never officially disclosed by either company. What followed was not a clean integration: a little over a year later, in July 2023, Pristyn Care suspended both Lybrate co-founders after they served the company a default notice alleging it had not paid what it owed them from the acquisition, and by December 2023, the founders had moved a United States court to begin arbitration against Pristyn Care, according to Tracxn’s company record. Both the scale of what Lybrate had built and the acrimony of how that value was eventually cashed out are captured in that single sequence of events.
The money behind it
Lybrate raised a comparatively modest amount by the standards of India’s later healthtech rounds, and did so across only three disclosed rounds before its 2022 sale.
- Angel/seed round, August 2014: $1.23 million, led by Nexus Venture Partners, with angel investors Gokul Rajaram (a former Google AdSense and Facebook Ads executive) and Vispi Daver also participating (Forbes India; Inc42 funding data).
- Series A, July 2015: $10.2 million, with Tiger Global Management, Nexus Venture Partners and Ratan Tata named as investors (Forbes India, TechCrunch, Wikipedia). Inc42’s own funding database separately lists Nexus Venture Partners as the round’s lead investor rather than Tiger Global — the two sources do not fully agree on who led the round, so both are named here.
- Venture round, April 2017: $3 million, investors undisclosed at the time and never subsequently named publicly (TechCrunch, Inc42).
- Total raised: $14.43 million across the three rounds above (Inc42, Tracxn, CB Insights).
- Exit, 7 June 2022: acquired outright by Pristyn Care; deal value not officially disclosed. Inc42 reporting from July 2023 put the figure in the $20-30 million range, describing it as unconfirmed.
No priced valuation for Lybrate itself — at seed, Series A, or at the point of acquisition — has been made public by the company or its investors.
How it makes money
Lybrate’s revenue model changed more than once as the company tried to convert a large, mostly free user base into paying transactions.
- Free tier: public doctor Q&A, a doctor-written health-content feed and health quizzes, used to build daily engagement without direct monetisation.
- Lybrate Consult: paid text, audio or video consultations between a patient and a chosen doctor; the platform’s cut or take-rate on these consultations has never been publicly disclosed.
- Lybrate Lab+ (from 2016): diagnostic test bookings with home sample pickup and online report sharing, monetised through lab partnerships rather than direct patient fees.
- Lybrate Cube: a subscription practice-management tool sold to doctors and clinics, aimed at the supply side of the marketplace rather than patients.
- Since the 2022 acquisition: the live site (accessed September 2026) now leads with a “Plan my Surgery” call to action and credits Pristyn Care as its “Surgery Partner” in the footer, indicating the platform’s primary current commercial function is generating elective-surgery leads for its parent company.
The part most outside observers get wrong is treating Lybrate as if it still operates as the independent, multi-revenue-stream consultation marketplace it was built to be. Its own most recent filed numbers — ₹11 lakh of revenue in FY25 — suggest the India entity itself now earns very little directly; the commercial value it built (doctor network, patient traffic, brand recall) appears to have migrated toward feeding Pristyn Care’s surgery business, value that would show up on Pristyn Care’s books rather than Lybrate’s.
The numbers
Lybrate’s financial history is thinly disclosed in public sources. The two data points available from around its funding peak, and the two most recent filed figures, show a business that shrank sharply rather than compounded — with a multi-year gap in between for which no public revenue or profit/loss figures were found this session, so none are invented here. No profit or loss figure for any year appears in the sources available.
| Fiscal year | Revenue (₹ crore) | Profit/loss (₹ crore) | Note / source |
| FY16 (2015-16) | 22.45 | Not disclosed | Reported turnover, as per company (Forbes India, 2017); roughly $2.34 million at $1≈₹96.0, 18 September 2026, Trading Economics |
| FY17 (2016-17) | 25 (target, not actual) | Not disclosed | Company-stated target for the year, not a confirmed actual (Forbes India, 2017) |
| FY24 (2023-24) | 1.0 | Not disclosed | Inc42 company financial data (accessed September 2026) |
| FY25 (2024-25) | 0.11 (₹11 lakh) | Not disclosed | Inc42 company financial data; down 89.1% year on year (accessed September 2026) |
Tracxn’s company profile separately bands Lybrate’s FY25 annual revenue at “₹0-10 crore,” which is consistent with, though less precise than, Inc42’s ₹11 lakh figure. Employee headcount was recorded at 162 as of August 2026 (Tracxn).
Where the money comes from
- Geographic split (2017): about 60% of traction came from tier-1 cities and 40% from tier-2 and tier-3 towns, per Forbes India’s 2017 reporting.
- Current footprint (September 2026, per lybrate.com): presence across seven metro cities — Mumbai, Pune, Delhi, Bangalore, Hyderabad, Chennai and Kolkata — plus over twenty listed tier-2 and tier-3 towns; a stated network of 150+ clinics, 800+ partner hospitals and 400+ super-specialist surgeons.
- Content and engagement scale (September 2026, lybrate.com): over 10 million questions answered by doctors on the platform, and over 18 million uses of its health quizzes — an engagement flywheel that is not itself a direct revenue line.
- The surprise: the channel that now sits front and centre on Lybrate’s own homepage is “Plan my Surgery,” not consultations or diagnostics. A company built to make many small doctor interactions easy now visibly optimises for one large, single-buyer transaction — a surgery referral to its own parent.
The risks
- Single-buyer dependency: Lybrate’s current homepage names Pristyn Care as its sole “Surgery Partner,” and its core current call to action funnels users toward surgery bookings rather than the broader multi-vertical model (consultations, diagnostics, doctor software) it ran independently before 2022. A platform whose commercial purpose has narrowed to feeding one buyer carries concentration risk if that commercial relationship changes.
- Unresolved payment dispute with its own acquirer: Lybrate’s co-founders were suspended by Pristyn Care in July 2023 after alleging they had not been paid in full for the 2022 sale, and by December 2023 had moved a US court for arbitration, per Tracxn’s company record. A dispute of this kind, still apparently unresolved in public reporting, signals unsettled terms around how the acquisition — and by extension the underlying business — was actually valued and paid for.
- Collapsing standalone revenue: the India entity’s own filed revenue fell from about ₹1.0 crore in FY24 to about ₹11 lakh in FY25, a drop of 89.1% year on year (Inc42). A business that once reported a turnover in the tens of crores now books next to nothing directly, raising questions about how much independent commercial activity remains inside the Lybrate entity itself, as distinct from its parent.
The takeaway
Lybrate did the hard part that most healthtech founders never manage: it built a genuinely large network, over 150,000 doctors and tens of millions of recorded interactions, on a real insight about unreachable doctors in a country short of them. What it never fully solved was turning that reach into a revenue engine that could keep raising capital on its own terms. After its last outside round in 2017, it went five years without a disclosed follow-on, and when the exit finally came, it came on someone else’s terms tight enough that its own founders ended up suing the acquirer for the money they say they were owed. The lesson is not that distribution or trust with users doesn’t matter — Lybrate’s numbers show it built plenty of both. It is that distribution has to convert into monetisable, defensible revenue before the capital runs out, or the network you built ends up working for whoever buys it next, on their terms rather than yours.
Frequently asked questions
What does Lybrate do today?
As of September 2026, Lybrate operates as an online doctor-consultation and health-content platform with over 150,000 listed doctors, but its own homepage now foregrounds surgery bookings and credits Pristyn Care, its owner since 2022, as its “Surgery Partner.”
Who founded Lybrate, and when?
Lybrate was founded in 2013 by Saurabh Arora, a former Facebook employee and IIT Delhi and Columbia Business School graduate, and Rahul Narang, a former lead software engineer at Snapdeal, who became the company’s CTO.
How much money did Lybrate raise before it was sold?
Lybrate raised $14.43 million in total across three disclosed rounds: $1.23 million in August 2014, $10.2 million in July 2015, and $3 million in April 2017, from investors including Nexus Venture Partners, Tiger Global Management and Ratan Tata.
Who acquired Lybrate, and why?
Pristyn Care, a surgical-care company, acquired Lybrate on 7 June 2022 to add an online-consultation and primary-care front end to its own surgery-focused business. The deal value was not officially disclosed; Inc42 later estimated it at $20-30 million.
What happened between Lybrate’s founders and Pristyn Care after the acquisition?
Lybrate’s founders alleged Pristyn Care had not paid the full consideration owed to them from the 2022 sale. Pristyn Care suspended both founders in July 2023 after they served it a default notice, and by December 2023 the founders had moved a US court to begin arbitration against the company, according to Tracxn.
Sources
Figures are as of September 2026. Currency converted at $1 ≈ ₹96.0 as of 18 September 2026 (Trading Economics).
- Wikipedia, “Lybrate” (accessed September 2026)
- Inc42, “4 Mn Downloads, 100K Doctors, $11.43 Mn Funding: Healthcare Platform Lybrate Looks To Close ‘Awareness-Engagement-Action’ Loop For Patients,” growth-story feature, metrics as of December 2016
- Forbes India, “With Lybrate, a doctor is just a click away,” 2017
- TechCrunch, “Lybrate raises $3M to help Indians manage their health from a smartphone,” 12 April 2017
- TechStory, Lybrate company profile and product-pivot account, 2015
- Tracxn, Lybrate company profile, financials and founders/board data (accessed September 2026)
- Inc42, Lybrate company financial and funding data pages (accessed September 2026)
- CB Insights, Lybrate company profile (accessed September 2026)
- Entrackr, “Pristyn Care suspends Lybrate founders after 12 months of its acquisition,” July 2023
- Inc42, “Pristyn Care Suspends Lybrate Cofounders For Filing Default Notice Against The Healthtech Unicorn,” July 2023
- Lybrate.com, official website (accessed September 2026)
- Trading Economics, USD/INR exchange rate, 18 September 2026
Found an error? Write to us and we’ll correct it in the open, dated, on the piece.